Tepmetko Drug Interactions
Currently displaying 214 drugs known to have a moderate interaction with Tepmetko (tepotinib).
Moderate interactions with Tepmetko (tepotinib)
Note: Showing generic names only.
A
- abametapir topical
- abiraterone
- afatinib
- aldesleukin
- aliskiren
- alpelisib
- ambrisentan
- aminoglutethimide
- amiodarone
- amlodipine
- amobarbital
- amprenavir
- apixaban
- aprepitant
- armodafinil
- artesunate
- asparaginase erwinia chrysanthemi
- asparaginase escherichia coli
- atazanavir
- atorvastatin
- avacopan
B
- bedaquiline
- betrixaban
- bexarotene
- bicalutamide
- black cohosh
- boceprevir
- bosentan
- bosutinib
- brentuximab
- brigatinib
- butabarbital
- butalbital
C
- calaspargase pegol
- canagliflozin
- cannabidiol
- capmatinib
- cenobamate
- ceritinib
- chloramphenicol
- cimetidine
- ciprofloxacin
- cladribine
- clofarabine
- clotrimazole
- cobimetinib
- crizotinib
- cyclosporine
D
- dabigatran
- dabrafenib
- daclizumab
- danazol
- danicopan
- darunavir
- dasatinib
- daunorubicin
- daunorubicin liposomal
- deferasirox
- delafloxacin
- delavirdine
- dexamethasone
- digoxin
- diltiazem
- doxorubicin
- doxorubicin liposomal
- dronedarone
- duvelisib
E
- efavirenz
- elagolix
- eltrombopag
- empagliflozin
- enasidenib
- encorafenib
- entrectinib
- epirubicin
- erlotinib
- erythromycin
- eslicarbazepine
- ethinyl estradiol
- etoposide
- etravirine
- everolimus
F
- fedratinib
- felbamate
- fexinidazole
- fexofenadine
- flibanserin
- fluconazole
- fluvoxamine
- fosamprenavir
- fosaprepitant
- fostamatinib
G
I
- ibrutinib
- idarubicin
- idelalisib
- imatinib
- indinavir
- interferon beta-1a
- interferon beta-1b
- irinotecan
- irinotecan liposomal
- isavuconazonium
- isoniazid
- istradefylline
- ivacaftor
- ivosidenib
L
- lanreotide
- lapatinib
- larotrectinib
- lasmiditan
- lefamulin
- lemborexant
- lesinurad
- letermovir
- lonapegsomatropin
- loperamide
- lorlatinib
- lurasidone
- lusutrombopag
M
N
O
P
- paclitaxel
- paclitaxel protein-bound
- palbociclib
- pasireotide
- pazopanib
- pegaspargase
- peginterferon beta-1a
- pentobarbital
- phenylbutazone
- pitolisant
- posaconazole
- pralsetinib
- propafenone
Q
R
- ranolazine
- remdesivir
- repotrectinib
- ribociclib
- rimegepant
- riociguat
- ripretinib
- risperidone
- rivaroxaban
- romidepsin
- rucaparib
- rufinamide
S
- sarecycline
- secobarbital
- selexipag
- selpercatinib
- silodosin
- sirolimus
- somapacitan-beco
- somatrem
- somatrogon
- somatropin
- sotorasib
- sulfasalazine
- sulfinpyrazone
- suvorexant
T
- tacrolimus
- talazoparib
- tazemetostat
- telotristat
- tenofovir
- tenofovir alafenamide
- thioguanine
- ticagrelor
- tipranavir
- tolvaptan
- topotecan
- trabectedin
- troglitazone
- troleandomycin
U
V
- valoctocogene roxaparvovec
- vemurafenib
- verapamil
- viloxazine
- vinblastine
- vincristine
- vincristine liposome
- vinorelbine
- voclosporin
- voriconazole
- voxelotor
Z
Tepmetko alcohol/food interactions
There is 1 alcohol/food interaction with Tepmetko (tepotinib).
Tepmetko disease interactions
There are 3 disease interactions with Tepmetko (tepotinib) which include:
Report options
QR code containing a link to this page
More about Tepmetko (tepotinib)
- Tepmetko consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
